Results 41 to 50 of about 2,498,926 (399)
MicroRNA410 Inhibits Pulmonary Vascular Remodeling via Regulation of Nicotinamide Phosphoribosyltransferase [PDF]
, 2019 Nicotinamide phosphoribosyltransferase (NAMPT) upregulation in human pulmonary artery endothelial cells (hPAECs) is associated with pulmonary arterial hypertension (PAH) progression and pulmonary vascular remodeling.
Chen, Jiwang +7 more
core +1 more source
MicroRNA-483 amelioration of experimental pulmonary hypertension. [PDF]
, 2020 Endothelial dysfunction is critically involved in the pathogenesis of pulmonary arterial hypertension (PAH) and that exogenously administered microRNA may be of therapeutic benefit.
Bai, Liang +22 more
core +1 more source
BMC Pulmonary Medicine, 2017 Background Chronic inflammation emerges as a feature of the pathogenesis of pulmonary arterial hypertension (PAH) in experimental models. Alterations of circulating cell subsets have been observed in patients with PAH.
Lars Harbaum +9 more
doaj +1 more source
Micro-RNA-1 is decreased by hypoxia and contributes to the development of pulmonary vascular remodeling via regulation of sphingosine kinase 1 [PDF]
, 2018 Sphingosine kinase 1 (SphK1) upregulation is associated with pathologic pulmonary vascular remodeling in pulmonary arterial hypertension (PAH), but the mechanisms controlling its expression are undefined.
Chen, Jiwang +6 more
core +1 more source
Riociguat for the treatment of chronic thromboembolic pulmonary hypertension. [PDF]
, 2013 BACKGROUND: Riociguat, a member of a new class of compounds (soluble guanylate cyclase stimulators), has been shown in previous clinical studies to be beneficial in the treatment of chronic thromboembolic pulmonary hypertension. METHODS: In this phase 3,
CHEST-1 Study Group, +13 more
core +1 more source
Pulmonary Hypertension Due to Left Heart Disease: Diagnosis, Pathophysiology, and Therapy.
HYPERTENSION, 2020 Pulmonary hypertension (PH) due to left heart disease (LHD) is the most common type of PH and is defined as mean pulmonary artery systolic pressure of >20 mm Hg and pulmonary capillary wedge pressure >15 mm Hg during right heart catheterization.
M. Al-Omary +4 more
semanticscholar +1 more source
Current Problems in Cardiology, 2004 Pulmonary hypertension, in its simplest sense, is elevation of the pulmonary artery pressure above normal. A multitude of diseases may increase the pulmonary artery pressure and result in right ventricular dysfunction. The treatments of pulmonary hypertension are as varied as its causes.
Vallerie V, McLaughlin, Stuart, Rich
openaire +2 more sources
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
Science Translational Medicine, 2020 ACTRIIA-Fc, an activin and GDF8/11 ligand trap, improves hemodynamics and exerts antiremodeling effects in experimental pulmonary hypertension. Remedying pulmonary vascular remodeling Alterations in bone morphogenetic protein, growth and differentiation ...
L. Yung +20 more
semanticscholar +1 more source
Macitentan in daily clinical practice: A single centre, 1-year experience
Pulmonology, 2018 The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events.
S. Cadenas-Menéndez +5 more
doaj +3 more sources
Pulmonary Circulation, 2022 Even though pulmonary arterial hypertension (PAH) remains an incurable disease, the combination of PAH‐specific therapies allowed treatment strategies to evolve from symptom‐based ones to others that aim to move patients to low‐risk conditions ...
Abdullah M. Aldalaan +7 more
doaj +1 more source